ID   U-2932
AC   CVCL_1896
SY   U2932
DR   EFO; EFO_0006499
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-4527
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473452
DR   cancercelllines; CVCL_1896
DR   ChEMBL-Cells; CHEMBL4295421
DR   ChEMBL-Targets; CHEMBL4296507
DR   Cosmic; 1487546
DR   Cosmic; 1517654
DR   Cosmic; 1945196
DR   DSMZ; ACC-633
DR   DSMZCellDive; ACC-633
DR   EGA; EGAS00001000610
DR   GEO; GSM1035339
DR   GEO; GSM1059802
DR   GEO; GSM1374971
DR   PharmacoDB; U2932_1621_2019
DR   PRIDE; PXD000589
DR   Progenetix; CVCL_1896
DR   PubChem_Cell_line; CVCL_1896
DR   Ubigene; YC-C059
DR   Wikidata; Q54973560
RX   PubMed=12533045;
RX   PubMed=20054396;
RX   PubMed=23257783;
RX   PubMed=23292937;
RX   PubMed=23295736;
RX   PubMed=25485619;
RX   PubMed=25894527;
RX   PubMed=26589293;
RX   PubMed=27566572;
RX   PubMed=28196595;
RX   PubMed=29416618;
RX   PubMed=29533902;
RX   PubMed=29666304;
RX   PubMed=30165192;
RX   PubMed=31160637;
WW   https://tcpaportal.org/mclp/
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572).
CC   Doubling time: 48 hours (PubMed=12533045); ~50 hours (DSMZ=ACC-633).
CC   HLA typing: A*01:01,03:01; B*08:01,15:01; C*03:04,07:01 (PubMed=26589293).
CC   HLA typing: A*01:01:01,03:01:01; B*08:01:01,15:01:01; C*03:04:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,03:01:01; DQA1*03:01:01,05:01:01; DQB1*02:01:01,03:02:01; DRA*01:01:01,01:02:02; DRB1*03:01:01,04:01:01 (DSMZCellDive=ACC-633).
CC   Omics: Array-based CGH.
CC   Omics: Cell surface proteome.
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Donor information: Originally the patient was suffering from Hodgkin lymphoma.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 15
ST   D19S433: 14
ST   D21S11: 28,29,30
ST   D2S1338: 22,23
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 9,13
ST   D8S1179: 13,14
ST   FGA: 22,24
ST   Penta D: 12
ST   Penta E: 13,14
ST   TH01: 9.3
ST   TPOX: 11,12
ST   vWA: 14,17
DI   NCIt; C36081; Diffuse large B-cell lymphoma activated B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=12533045; DOI=10.1080/1042819021000032917;
RA   Amini R.-M., Berglund M., Rosenquist R., von Heideman A.,
RA   Lagercrantz S., Thunberg U., Bergh J., Sundstrom C., Glimelius B.,
RA   Enblad G.;
RT   "A novel B-cell line (U-2932) established from a patient with diffuse
RT   large B-cell lymphoma following Hodgkin lymphoma.";
RL   Leuk. Lymphoma 43:2179-2189(2002).
//
RX   PubMed=20054396; DOI=10.1038/nature08638;
RA   Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B.,
RA   Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III,
RA   Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A.,
RA   Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M.,
RA   Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M.;
RT   "Chronic active B-cell-receptor signalling in diffuse large B-cell
RT   lymphoma.";
RL   Nature 463:88-92(2010).
//
RX   PubMed=23257783; DOI=10.1038/leu.2012.367;
RA   Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H.,
RA   Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S.,
RA   Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.;
RT   "MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";
RL   Leukemia 27:1381-1390(2013).
//
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
//
RX   PubMed=23295736; DOI=10.1038/leu.2012.358;
RA   Quentmeier H., Amini R.-M., Berglund M., Dirks W.G., Ehrentraut S.,
RA   Geffers R., MacLeod R.A.F., Nagel S., Romani J., Scherr M.,
RA   Zaborski M., Drexler H.G.;
RT   "U-2932: two clones in one cell line, a tool for the study of clonal
RT   evolution.";
RL   Leukemia 27:1155-1164(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27566572; DOI=10.18632/oncotarget.11524;
RA   Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V.,
RA   MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C.,
RA   Zaborski M., Drexler H.G.;
RT   "Subclones in B-lymphoma cell lines: isogenic models for the study of
RT   gene regulation.";
RL   Oncotarget 7:63456-63465(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//
RX   PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020;
RA   Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D.,
RA   Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P.,
RA   Lossos I.S., Landgraf R., Vega-Vazquez F.;
RT   "Smoothened stabilizes and protects TRAF6 from degradation: a novel
RT   non-canonical role of smoothened with implications in lymphoma
RT   biology.";
RL   Cancer Lett. 436:149-158(2018).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//